Abstract
Approximately 4% of all individuals that develop pulmonary embolism will go on to have chronic thromboembolic pulmonary hypertension (CTEPH). Patients with severe CTEPH will eventually be evaluated for thrombendarterectomy, the only curative treatment for this disease. However, only a subgroup of these patients is eligible for this invasive procedure. In addition, a number of patients will not benefit tremendously from thrombendarterectomy. Finally, thrombendarterectomy may not be possible for functional reasons. In these situations medical treatment, i.e. diuretics, oxygen and anticoagulation remains and is recommended. However, no proven specific e.g. vasodilating medical treatment has been demonstrated in CTEPH. Patients with CTEPH exhibit the same symptoms and a comparable prognosis compared with pulmonary arterial hypertension (PAH) patients. Although the occlusion of pulmonary vessels in CTEPH is caused by repetitive embolism histological similarities to PAH were observed in the pulmonary vascular bed, possibly a reaction to the developing high vascular pressure. Considering these similarities it would certainly make sense to study medical PAH treatment in patients with CTEPH. A few smaller studies exist, which do suggest beneficial effects of endothelin receptor antagonists, prostanoids and phosphodiesterase-5 antagonists in CTEPH. The evidence for the various forms of treatment of for CTEPH will be reviewed.
Keywords: Pulmonary embolism, pulmonary hypertension, thrombendarterectomy, drug therapy, lung transplantation
Current Respiratory Medicine Reviews
Title: Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options
Volume: 2 Issue: 4
Author(s): Hans-Jurgen Seyfarth, Stefan Hammerschmidt, Christian Gessner, Michael Halank and Hubert Wirtz
Affiliation:
Keywords: Pulmonary embolism, pulmonary hypertension, thrombendarterectomy, drug therapy, lung transplantation
Abstract: Approximately 4% of all individuals that develop pulmonary embolism will go on to have chronic thromboembolic pulmonary hypertension (CTEPH). Patients with severe CTEPH will eventually be evaluated for thrombendarterectomy, the only curative treatment for this disease. However, only a subgroup of these patients is eligible for this invasive procedure. In addition, a number of patients will not benefit tremendously from thrombendarterectomy. Finally, thrombendarterectomy may not be possible for functional reasons. In these situations medical treatment, i.e. diuretics, oxygen and anticoagulation remains and is recommended. However, no proven specific e.g. vasodilating medical treatment has been demonstrated in CTEPH. Patients with CTEPH exhibit the same symptoms and a comparable prognosis compared with pulmonary arterial hypertension (PAH) patients. Although the occlusion of pulmonary vessels in CTEPH is caused by repetitive embolism histological similarities to PAH were observed in the pulmonary vascular bed, possibly a reaction to the developing high vascular pressure. Considering these similarities it would certainly make sense to study medical PAH treatment in patients with CTEPH. A few smaller studies exist, which do suggest beneficial effects of endothelin receptor antagonists, prostanoids and phosphodiesterase-5 antagonists in CTEPH. The evidence for the various forms of treatment of for CTEPH will be reviewed.
Export Options
About this article
Cite this article as:
Seyfarth Hans-Jurgen, Hammerschmidt Stefan, Gessner Christian, Halank Michael and Wirtz Hubert, Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options, Current Respiratory Medicine Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339806778777186
DOI https://dx.doi.org/10.2174/157339806778777186 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Redox Mechanisms of Vascular Cell Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Technological Barriers in the Use of Electrochemical Microsensors and Microbiosensors for in vivo Analysis of Neurological Relevant Substances
Current Neuropharmacology Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Statins Influence Long Term Restenosis and Cardiovascular Events Following Carotid Endarterectomy
Current Vascular Pharmacology Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Evaluation of LVDD by CCTA with Dual-source CT in Type 2 Diabetes Mellitus Patients
Current Medical Imaging Effects of Pterostilbene on Diabetes, Liver Steatosis and Serum Lipids
Current Medicinal Chemistry H<sub>3</sub>PW<sub>12</sub>O<sub>40</sub>-Catalyzed Multicomponent Reaction for Efficient Synthesis of Highly Substituted Piperidines
Combinatorial Chemistry & High Throughput Screening Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Angiotensin II Regulates Vascular and Endothelial Dysfunction: Recent Topics of Angiotensin II Type-1 Receptor Signaling in the Vasculature
Current Vascular Pharmacology Crystal Structures of Phosphodiesterases and Implications on Substrate Specificity and Inhibitor Selectivity
Current Topics in Medicinal Chemistry Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Secondary Hypertension in Children and Adolescents: Novel Insights
Current Hypertension Reviews Nutrient-Induced Insulin Resistance in Human Skeletal Muscle
Current Medicinal Chemistry Investigation of Gene Expression Pattern of 5HTR2a and MAO-A in PBMCs of Individuals Who Had Been Exposed to Air Pollution in Highly Polluted Area
Recent Patents on Inflammation & Allergy Drug Discovery Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design The Gender Bender effect in Periodontal Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets A Versatile Stability-indicating Liquid Chromatographic Method for the Simultaneous Determination of Atenolol, Hydrochlorothiazide and Chlorthalidone
Current Pharmaceutical Analysis Stroke Outcomes in Mice Lacking the Genes for Neuronal Heme Oxygenase-2 and Nitric Oxide Synthase
Current Neurovascular Research